Last reviewed · How we verify
Grass pollen formulation — Competitive Intelligence Brief
phase 3
Allergen immunotherapy (AIT)
Immunology / Allergy
Biologic
Live · refreshed every 30 min
Target snapshot
Grass pollen formulation (Grass pollen formulation) — Allergopharma GmbH & Co. KG. A grass pollen allergen extract that desensitizes the immune system to grass pollen allergens through repeated controlled exposure.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Grass pollen formulation TARGET | Grass pollen formulation | Allergopharma GmbH & Co. KG | phase 3 | Allergen immunotherapy (AIT) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Allergen immunotherapy (AIT) class)
- Allergopharma GmbH & Co. KG · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Grass pollen formulation CI watch — RSS
- Grass pollen formulation CI watch — Atom
- Grass pollen formulation CI watch — JSON
- Grass pollen formulation alone — RSS
- Whole Allergen immunotherapy (AIT) class — RSS
Cite this brief
Drug Landscape (2026). Grass pollen formulation — Competitive Intelligence Brief. https://druglandscape.com/ci/grass-pollen-formulation. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab